Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 4/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3267632 | 0.79 | ERN1 (0.35) | ERN1GSK3BAR | |
| SCHEMBL3267448 | 0.79 | ERN1 (0.42) | ERN1CA12 | |
| SCHEMBL3268893 | 0.76 | ERN1 (0.41) | ERN1 | |
| SCHEMBL3267174 | 0.76 | CYP3A4 (0.34) | ERN1 | |
| SCHEMBL30975518 | 0.72 | CA1 (0.37) | ERN1CA12CA1CA2CA7 | |
| SCHEMBL5420882 | 0.72 | CA1 (0.37) | ERN1CA12CA1CA2CA7 | |
| SCHEMBL1013026 | 0.72 | ERN1 (0.40) | ERN1 | |
| SCHEMBL31438987 | 0.72 | ERN1 (0.40) | ERN1 | |
| SCHEMBL1418396 | 0.72 | ERN1 (0.42) | ERN1 | |
| SCHEMBL29504018 | 0.72 | ERN1 (0.42) | ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1914229-B1 | NOVEL CERCOSPORAMIDE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2010-06-16 | — | — | EP | disclosed |
| US-20090036492-A1 | Novel Cercosporamide Derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1914229-A1 | NOVEL CERCOSPORAMIDE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036492-A1 | Novel Cercosporamide Derivative | GPR119, CBR3, SLC5A2 | ERN1 337/4885GSK3B 4430/4885CA12 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.